Notable among the capital expenditures carried out at Group level were a new packaging plant at the Romanian manufacturing unit as well as a small volume granulation unit at our Russian subsidiary.

In line with the strategic goal of improving its share of high intellectual value intensive production and taking advantage of a sound knowledge in the field of large scale fermentation procedures the Company has entered into the development of biosimilar research and manufacturing capacities. Following the acquisition in 2007 in Germany of a manufacturing unit dedicated towards the development of bacterial fermentation together with a related pilot plant and laboratory, Richter announced in 2008 a greenfield investment to be carried out in the Hungarian city of Debrecen aimed at the manufacturing of biosimilar products by means of mammalian cell fermentation. Construction works of the building were finished during 2009 together with the major energy supplying (steam and hot water boilers, coolers, compressors, transformers) and transporting systems. Capital expenditure related to research, development and manufacturing of biological products in Hungary amounted to HUF 7,814 million (EUR 27.8 million) in 2009. The plant is expected to be operational in 2012.